Carcinoma of urinary bladder
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: (1) All patients with bladder cancer; (2) Time frame: Patients who were diagnosed with bladder cancer through pathological examination and received treatment at our hospital from January 1, 2000 to December 31, 2025; (3) Data completeness: The patients included in the study must have comprehensive and systematic clinical records, detailed pathological data, clear information on the pathological type, grade, stage, etc. of the tumor, as well as complete follow-up data, documenting the patient's condition changes, survival status, recurrence and metastasis after treatment.
Exclusion criteria
Exclusion criteria: (1)Inconsistent disease type: Patients whose discharge diagnosis was confirmed as not bladder cancer after examination; (2)Data deficiency: There is a lack of key information in the clinical records, such as the absence of necessary auxiliary examination results, insufficient diagnostic basis, and unclear treatment plans, which makes it impossible to accurately assess the patient's condition and treatment outcome; (3)Patients with incomplete clinical data; (4)Patients who refused to provide information about their condition during follow-up and whose cause of death could not be determined; (5)Secondary bladder cancer.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Gender(1 = Male, 2 = Female);Age (Year);TNM staging;Tumor pathological classification (1 = urothelial carcinoma; 2 = squamous cell carcinoma; 3 = adenocarcinoma; 4 = rhabdomyosarcoma; 5 = pheochromocytoma; 6 = mixed tumor);Tumor status at the initial diagnosis (1 = NMIBC (Tis/Ta/T1); 2 = MICB with local progression without lymph node metastasis; 3 = MICB with local progression and lymph node metastasis; 4 = distant metastasis);T(1=Tis/Ta/T1; 2=T2a; 3=T2b; 4=T3a; 5=T3b; 6=T4a;7=T4b);lymphatic metastasis(0=No;1=Yes);Distant metastasis(0=No;1=Yes);Number of tumors (1 = single; 2 = multiple);Postoperative tumor recurrence (0 = no; 1 = recurrence);Tumor pathological grading (grades 1, 2, and 3);Postoperative tumor metastasis deterioration (0 = no; 1 = yes);Treatment methods (1 = TURBT, 2 = Radical Cystectomy, 3 = Palliative Treatment, 4 = Passive Treatment, 5 = Partial Cystectomy, 6 = Nephrostomy, 7 = Internal Iliac Artery Catheter Chemotherapy, 8 = Care Treatment, 9 = Bladder Puncture Fistulation, 10 = Non-tumor Symptomatic Treatment, 11 = Chemoradiotherapy);Comorbidities include hypertension (0 = no; 1 = yes);Comorbidities include diabetes (0 = no; 1 = yes);Comorbidities include coronary heart disease (0 = no; 1 = yes);Comorbidities include COPD (0 = no; 1 = yes);Associated with the disease was cerebral hemorrhage (0 = no; 1 = yes);Associated with the disease was cerebral infarction (0 = no; 1 = yes);Associated with the disease was the infection with the novel coronavirus (0 = no; 1 = yes);Associated diseases include pulmonary infection (0 = no; 1 = yes);Associated diseases include urinary tract infection (0 = no; 1 = yes);Classification of causes of death (0 = survived; 1 = death related to tumor; 2 = death unrelated to tumor);Death diseases (0 = survival, 1 = hypertension, 2 = diabetes, 3 = coronary heart disease, 4 = COPD, 5 = cerebral hemorrhage, 6 = cerebral infarction, 7 = COVID-19 infection, 8 = traffic accident accident, 9 = medication, suicide by jumping, 10 = | — |
Countries
China
Contacts
Affiliated hospital of Zunyi Medical University